
Hyperfine (HYPR) Stock Forecast & Price Target
Hyperfine (HYPR) Analyst Ratings
Bulls say
Hyperfine is a strong buy for investors as the company has proven sales and revenue, with continued growth expected through advancements in technology. The Swoop System, approved for use in various clinical settings, has shown significant positive results in reducing MRI turnaround time and is expected to reach breakeven in a short timeline. However, risks such as competition and regulatory approvals should be considered by potential investors.
Bears say
Hyperfine is an innovative medical device company with potential to revolutionize patient care through its portable, affordable, and clinically relevant AI-powered MRI technology. However, there are some fundamental factors that could negatively impact its operations, including regulatory risks, slow adoption of its Swoop system, and lumpiness in quarterly performance due to a relatively small and developing install base. Additionally, Hyperfine will need to effectively execute and ramp up revenue to reach its projected growth, which may be challenging given the longer sales cycle for hospitals and the competitive landscape in the medical device industry.
This aggregate rating is based on analysts' research of Hyperfine and is not a guaranteed prediction by Public.com or investment advice.
Hyperfine (HYPR) Analyst Forecast & Price Prediction
Start investing in Hyperfine (HYPR)
Order type
Buy in
Order amount
Est. shares
0 shares